What the research found

A survey of over 2,100 people currently taking creatine revealed that cognitive enhancement was the primary motivation for roughly two-thirds of users. However, only about one-third of those seeking cognitive benefits reported that creatine actually delivered noticeable effects for them. Despite this disconnect, the vast majority of respondents said they would continue supplementing regardless.

The data comes from real-world users rather than controlled trial participants, which provides insight into how people actually use creatine outside laboratory conditions. The authors suggest the gap between expectation and perceived outcome might reflect suboptimal dosing strategies rather than an absence of cognitive benefit—implying that users seeking brain effects may not be timing or dosing creatine optimally for that particular goal.

Why it matters for you

If you're taking creatine primarily for cognition, this survey highlights a practical problem: most people doing so aren't experiencing the effect they want. Creatine's cognitive mechanism (primarily supporting phosphocreatine pools in the brain during high mental demand) may require specific dosing protocols—loading phases or consistent daily intake at adequate doses—that differ from muscle-building protocols. If you're tracking mental performance as a biomarker (reaction time, focus during work, decision-making under fatigue), you may need to audit whether your current creatine regimen matches evidence-based dosing for brain function rather than muscle.

The high adherence rate despite modest perceived benefit is also telling: it suggests either placebo effects are substantial, users expect delayed benefits, or creatine is delivering benefits they don't consciously detect. For a MyKine user, this is worth distinguishing through objective markers—cognitive testing apps, productivity logging, or sleep quality—rather than relying on subjective feeling alone.

Caveats

  • Self-reported outcomes only: Perceived cognitive benefit is subjective and prone to placebo effects, confirmation bias, and recall error
  • No baseline or control data: Survey doesn't include non-users or placebo comparators to establish what effect size is realistic
  • Confounding variables uncontrolled: Respondents differ in dosing, duration, diet, sleep, training status, and concurrent supplements—all of which influence outcomes
  • Industry affiliation: Published by SuppCo, a supplement company; potential for selection bias toward its customer base
  • Mechanism unexamined: Survey captures only user experience, not whether creatine actually reached effective brain concentrations in these individuals